To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Must have met the inclusion criteria for preceding double-blind study.

• Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria:

• Pregnant or considering becoming pregnant.

• Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.